Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Accretive Health, Inc.    

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Accretive Health, Inc. : Accretive Health Reports Inducement Grant under NYSE Rule 303A.08

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2013 | 07:05am EST

Accretive Health, Inc. (NYSE: AH) today announced that pursuant to the employment agreement entered into with Stephen Schuckenbrock on April 2, 2013, the company granted to Mr. Schuckenbrock on April 3, 2013 a non-qualified stock option under the New York Stock Exchange inducement grant exception. The inducement grant was approved by the company's Board of Directors on April 1, 2013 and is being made as an inducement material to Mr. Schuckenbrock's acceptance of employment with the company, in accordance with New York Stock Exchange Rule 303A.08. The company previously announced that Mr. Schuckenbrock has been appointed President and Chief Executive Officer and a member of the company's Board of Directors, effective April 3, 2013.

The stock option is for the purchase of 2,903,801 shares of the company's common stock, with an exercise price of $9.56, which was the closing price of the company's common stock reported on the New York Stock Exchange on April 3, 2013. The stock option will vest and become exercisable on a ratable monthly basis over 48 months based on continued service to the company, subject to acceleration in specified circumstances.

Accretive Health is providing the above information regarding Mr. Schuckenbrock's inducement grant in accordance with New York Stock Exchange Rule 303A.08.

About Accretive Health

At Accretive Health, our mission is to help our healthcare clients strengthen their financial stability and deliver better care at a more affordable cost to the communities they serve (increasing healthcare access to all). For more information, visit www.accretivehealth.com.

Accretive Health, Inc.
Investor Relations:
Atif Rahim
Telephone: 312.324.5476
email: investorrelations@accretivehealth.com
or
Media:
Puneet Singh
Telephone: 330.565.6802
email: mediarelations@accretivehealth.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACCRETIVE HEALTH, INC.
02/15 R1 RCM to Release Fourth Quarter and Full Year 2016 Results on March 1
2014 ACCRETIVE HEALTH, INC. : Accretive Health Provides Restatement Update
2014 ACCRETIVE HEALTH, INC. : Patrick Funck Joins Accretive Health as Chief Informati..
2014 ACCRETIVE HEALTH, INC. : Accretive Health Continues Company Restructuring
2013DJD. E. SHAW & CO. LP 3Q 13F : Largest Purchases -2-
2013DJD. E. SHAW & CO. LP 3Q 13F : Largest Purchases
2013DJCR INTRINSIC INVESTORS 3Q 13F : Largest Purchases -2-
2013DJCR INTRINSIC INVESTORS 3Q 13F : Largest Purchases
2013DJCR INTRINSIC INVESTORS 3Q 13F : Holdings As Of Sep -2-
2013DJCR INTRINSIC INVESTORS 3Q 13F : Holdings As Of Sep 30
More news
Sector news : Ambulance & Emergency Services
01/31DJHCA : Gives Upbeat Forecast as Quarterly Profit Tops Views
01/25DJDAVITA : Judge Blocks Rule That Would Limit Premium Assistance for Dialysis Pati..
01/12DJDAVITA : Judge Blocks Rule That Could Limit Premium Assistance for Dialysis Pati..
01/06DJFRESENIUS MEDICAL CARE : Impact Of Potential Regulation Change
2016 FTSE nudges higher though banks, Ashtead slide
More sector news : Ambulance & Emergency Services
Advertisement
Financials ($)
Sales 2016 207 M
EBIT 2016 -36,3 M
Net income 2016 -
Finance 2016 20,6 M
Yield 2016 -
P/E ratio 2016 3,13
P/E ratio 2017
EV / Sales 2016 1,10x
EV / Sales 2017 0,57x
Capitalization 249 M
More Financials
Chart ACCRETIVE HEALTH, INC.
Duration : Period :
Accretive Health, Inc. Technical Analysis Chart | US00438V1035 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 3,75 $
Spread / Average Target 61%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Gerard Flanagan President, Chief Executive Officer & Director
Steve J. Shulman Chairman
Christopher Simon Ricaurte Chief Financial Officer & Treasurer
Alex J. Mandl Independent Director
Charles J. Ditkoff Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACCRETIVE HEALTH, INC.-12.68%249
FRESENIUS SE & CO KGAA1.32%44 191
HCA HOLDINGS INC14.33%31 710
FRESENIUS MEDICAL CARE..-5.66%24 743
LABORATORY CORP. OF AM..8.73%14 378
QUEST DIAGNOSTICS INC4.07%13 260
More Results